





PATIENT ID:

FH.12091159

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

AGE: 28 Years

SEX: Male

ABHA NO:

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

31/10/2022 13:15:26

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status <u>Final</u>	Results		Biological Reference Interval U	
KIDNEY PANEL - 1				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	11		6 - 20	
METHOD : UREASE - UV			0 20	mg/dL
CREATININE EGFR- EPI				
CREATININE	1.18		0.90 - 1.30	740
METHOD: ALKALINE PICRATE KINETIC JAFFES			0.90 - 1.50	mg/dL
AGE	28			1/02/0
GLOMERULAR FILTRATION RATE (MALE)	86.20		Refer Interpretation Below	years
METHOD: CALCULATED PARAMETER			iterer interpretation below	mL/min/1
BUN/CREAT RATIO				
BUN/CREAT RATIO	9.32		5.00 - 15.00	
METHOD: CALCULATED PARAMETER			3.00 - 13.00	
URIC ACID, SERUM				
URIC ACID	8.8	High	3.5 - 7.2	
METHOD : URICASE UV		9	5.5 - 7.2	mg/dL
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	8.0		6.4 - 8.2	22.6.14
METHOD: BIURET			0.4 - 6.2	g/dL
ALBUMIN, SERUM				
ALBUMIN	4.5		3.4 - 5.0	2012
METHOD: BCP DYE BINDING			3.4 - 3.0	g/dL
GLOBULIN	CT.			
GLOBULIN	3.5		2.0 - 4.1	G MC1
METHOD: CALCULATED PARAMETER	0.0		2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM	139		126 145	
METHOD: ISE INDIRECT	133		136 - 145	mmol/L
POTASSIUM	4.13		3.50 5.10	2000 C.
METHOD: ISE INDIRECT			3.50 - 5.10	mmol/L
CHLORIDE	103		98 - 107	
METHOD: ISE INDIRECT	V.S.T.T.		20 - 10/	mmol/L

Interpretation(s)
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



Scan to View Details



Scan to View Report









PATIENT NAME: MR. MR.ANIL REDDY DAMMA

PATIENT ID:

FH.12091159

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

AGE: 28 Years SEX: Male

ABHA NO:

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

31/10/2022 13:15:26

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status

Final

Results

Biological Reference Interval

Uni

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPIGFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle w product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted a A GFR of 60 or higher is in the normal range.

A GFR below 50 are made in the blood.

A GFR below 50 are made in the product of the second into the sec

A GFR below 60 may mean kidney disease. A GFR of 15 or lower may mean kidney failure.

A GFR of 15 or lower may mean kidney failure. Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Re Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone. The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimates of the properties with higher GFR. This results in reduced misclassification of CKD. The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediat URIC ACID, SERUM-

Causes of Increased levels Dietary

- · High Protein Intake
- Prolonged Fasting,
 Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM. Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake
- · OCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Limit animal proteins

- High Fibre foods
 Vit C Intake
 Antioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin a

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic ALBUMIN, SERUM-

ALBUMIN, SERUMHuman serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUM-Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage relacidosis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tul adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in persistent gastric secretion and prolonged vomiting,

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report









PATIENT ID:

FH.12091159

CLIENT PATIENT ID: UID:12091159

ACCESSION NO: 0022VJ006201

AGE: 28 Years

SEX: Male

ABHA NO:

REPORTED:

31/10/2022 13:15:26

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

UID:12091159 REONO-1313831

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Unit
	HAEMATOLOGY			
CBC-5, EDTA WHOLE BLOOD				
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	16.6		13.0 - 17.0	g/dL
METHOD: SPECTROPHOTOMETRY				5/ 4-
RED BLOOD CELL (RBC) COUNT	5.09		4.5 - 5.5	mil/µL
METHOD: ELECTRICAL IMPEDANCE				πη, με
WHITE BLOOD CELL (WBC) COUNT	6.04		4.0 - 10.0	thou/µL
METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(D	HSS)CYTOMETRY		115.760 (Co. 25.55.55)	circu, pr
PLATELET COUNT	271		150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE				tilos/ pc
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	48.6		40 - 50	%
METHOD : CALCULATED PARAMETER			10 30	70
MEAN CORPUSCULAR VOLUME (MCV)	95.5		83 - 101	fL
METHOD: CALCULATED PARAMETER				12
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	32.7	High	27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER		100		P9
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	34.2		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.5	High	11.6 - 14.0	%
METHOD: CALCULATED PARAMETER				70
MENTZER INDEX	18.8			
MEAN PLATELET VOLUME (MPV)	8.9		6.8 - 10.9	fL
METHOD: CALCULATED PARAMETER			0.0 10.5	ΪĒ
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	52		40 - 80	0/
METHOD : FLOW CYTOMETRY	-		40 - 60	%
LYMPHOCYTES	35		20 - 40	0/
METHOD : FLOW CYTOMETRY	-		20 - 40	%
MONOCYTES	10		2 - 10	62
METHOD : FLOW CYTOMETRY	**		2 - 10	%
EOSINOPHILS	3		1 - 6	%
	TO		T 0	300

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

METHOD: FLOW CYTOMETRY

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -







Scan to View Report



%







PATIENT ID: FH.12091159

ACCESSION NO: 0022VJ006201

AGE: 28 Years SEX: Male ABHA NO:

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

31/10/2022 13:15:26 REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLIENT PATIENT ID: UID:12091159

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILL NO-1501220PCR054258

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Unit
	_	2. 2	%
BASOPHILS	0	0 - 2	70
METHOD: FLOW CYTOMETRY	0.44	20.70	thou/ul
ABSOLUTE NEUTROPHIL COUNT	3.14	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			77
ABSOLUTE LYMPHOCYTE COUNT	2.11	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.60	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER	02 Jane		31 1 -1
ABSOLUTE EOSINOPHIL COUNT	0.18	0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER			20 2 2
ABSOLUTE BASOPHIL COUNT	0	Low 0.02 - 0.10	thou/µL
METHOD: CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.5		
METHOD: CALCULATED PARAMETER			
MORPHOLOGY			
RBC	PREDOMINANT	Y NORMOCYTIC NORMOCHROMIC	
METHOD: MICROSCOPIC EXAMINATION			
WBC	NORMAL MORPI	HOLOGY	
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE		
METHOD: MICROSCOPIC EXAMINATION			

(ESR), WHOLE BLOOD

mm at 1 hr 03 0 - 14E.S.R

METHOD: WESTERGREN METHOD

Interpretation(s)
RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

oragnosing a case or beta transsaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







Scan to View Report









CLIENT PATIENT ID: UID:12091159 FH.12091159 PATIENT ID:

ABHA NO: SEX: Male AGE: 28 Years ACCESSION NO: 0022VJ006201

31/10/2022 13:15:26 RECEIVED: 31/10/2022 09:47:33 REPORTED: DRAWN: 31/10/2022 09:47:00

REFERRING DOCTOR: SELF CLIENT NAME : FORTIS VASHI-CHC -SPLZD

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status

Results

Biological Reference Interval

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

IEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE B **ABO GROUP**

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

BIO CHEMISTRY

CORONARY RISK PROFILE(LIPID PROFILE), SERUM

CHOLESTEROL, TOTAL

201

High < 200 Desirable

mg/dL

mg/dL

200 - 239 Borderline High

>/= 240 High

< 150 Normal

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: ENZYMATIC ASSAY

SRL Ltd

TRIGLYCERIDES

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





SEX: Male





PATIENT NAME: MR. MR.ANIL REDDY DAMMA

PATIENT ID: FH.12091159 CLIENT PATIENT ID: UID:12091159

ACCESSION NO: 0022VJ006201

AGE: 28 Years

ABHA NO:

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED: 31/10/2022 13:15:26

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258

BILLNO-1501220PCR054258 Text Beneat Status Final Results			Biological Reference Interval		
Test Report Status	<u>Final</u>	Results	_	Diological Reference	
HDL CHOLESTEROL		39	Low	< 40 Low >/=60 High	mg/dL
METHOD: DIRECT MEASUR LDL CHOLESTEROL, D	DIRECT	141	High	< 100 Optimal 100 - 129 Near or above op 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL timal
	RE WITHOUT SAMPLE PRETR		***	Desirebles Land thors 120	mg/dL
NON HDL CHOLESTER	ROL	162	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	<u>J.</u>
METHOD: CALCULATED P.	ARAMETER		112		
CHOL/HDL RATIO		5.2	High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
METHOD: CALCULATED P	ARAMETER	3.6	High	0.5 - 3.0 Desirable/Low Ris	:k
LDL/HDL RATIO		3.6	mgm	3.1 - 6.0 Borderline/Moder >6.0 High Risk	
METHOD : CALCULATED P	PARAMETER				× ****
VERY LOW DENSITY	LIPOPROTEIN	17.2		= 30.0</td <td>mg/dL</td>	mg/dL
METHOD : CALCULATED F	PARAMETER				
LIVER FUNCTION	PROFILE, SERUM				
BILIRUBIN, TOTAL		0.68		0.2 - 1.0	mg/dL
METHOD : JENDRASSIK A	AND GROFF				
BILIRUBIN, DIRECT		0.18		0.0 - 0.2	mg/dL
METHOD : JENDRASSIK A	AND GROFF				
BILIRUBIN, INDIREC		0.50		0.1 - 1.0	mg/dL
METHOD : CALCULATED I					
TOTAL PROTEIN		8.0		6.4 - 8.2	g/dL
METHOD : BIURET					
ALBUMIN		4.5		3.4 - 5.0	g/dL
METHOD : BCP DYE BING	DING				
GLOBULIN		3.5		2.0 - 4.1	g/dL
METHOD : CALCULATED	PARAMETER				
ALBUMIN/GLOBULIN	N RATIO	1.3		1.0 - 2.1	RATIO
SRL Ltd		mx38480m		(a) 572-866 (a)	Page 6 Of 11

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



Scan to View Details



Scan to View Report









FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

AGE: 28 Years SEX: Male

RECEIVED: 31/10/2022 09:47:33

ABHA NO:

31/10/2022 13:15:26 REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

DRAWN: 31/10/2022 09:47:00

CORP-OPD

BILLNO-1501220PCR054258

BILLNO-1501220PCR0	54258				
Test Report Status	Final	Results	2	Biological Reference Interva	I
METHOD: CALCULATED PAR	RAMETER				
ASPARTATE AMINOTRA	ANSFERASE (AST/SGOT)	28		15 - 37	U/L
METHOD: UV WITH P5P		 =1	Ulada	. 45 0	U/L
ALANINE AMINOTRANS	SFERASE (ALT/SGPT)	51	High	< 45.0	0/L
METHOD : UV WITH P5P		72		30 - 120	U/L
ALKALINE PHOSPHATA	SE	72		50 - 120	~, -
METHOD: PNPP-ANP GAMMA GLUTAMYL TR	ANGEEDAGE (GGT)	62		15 - 85	U/L
	YLCARBOXY 4NITROANILIDE	02			
LACTATE DEHYDROGE		154		100 - 190	U/L
METHOD : LACTATE -PYRUV					
GLUCOSE FASTING,	FLUORIDE PLASMA				
FBS (FASTING BLOOD	SUGAR)	110	High	74 - 99	mg/dL
METHOD: HEXOKINASE					
GLYCOSYLATED HE	MOGLOBIN(HBA1C), EDTA				
WHOLE BLOOD		5.2		Non-diabetic: < 5.7	%
HBA1C		5.2		Pre-diabetics: 5.7 - 6.4	
				Diabetics: > or = 6.5 ADA Target: 7.0	
				Action suggested: > 8.0	
METHOD: HB VARIANT (H	CASAN CONTRACTOR CONTR				
ESTIMATED AVERAGE	GLUCOSE(EAG)	102.5		< 116.0	mg/dL

METHOD: CALCULATED PARAMETER

Interpretation(s)
CORONARY RISK PROFILE(LIPID PROFILE), SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don to cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels of the diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn" t need into triglycerides, which are stored in fat cell triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, of diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determing provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consum and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery


SRI Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









Scan to View Report







CLIENT PATIENT ID: UID:12091159 PATIENT ID: FH.12091159

ABHA NO: SEX: Male 0022VJ006201 AGE: 28 Years ACCESSION NO:

RECEIVED: 31/10/2022 09:47:33 31/10/2022 13:15:26 REPORTED: DRAWN: 31/10/2022 09:47:00

REFERRING DOCTOR: SELF CLIENT NAME : FORTIS VASHI-CHC -SPLZD

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Biological Reference Interval Results **Test Report Status Final**

disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also t implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLD NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both pri and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used i patients for whom fasting is difficult.

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may giryellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg., hemolysis and ineffective erythropoiesis), decreased bilirubin excretion obstruction and hepatitis), and abnormal bilirubin metabolism (eg., hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin which there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin way be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme the attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measure.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measure clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemol anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the bloom is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein faund in almost all holy tissues. Tissues with bidney amounts of ALP is a protein faund in almost all holy tissues.

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstru Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancre is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the soun normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary syst and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, alknown as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Hellow is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood al levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vasc permeability or decreased lymphatic clearance, malnutrition and wasting etc GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted urine.

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals

while random serum glucose levels correlate with nome glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycalindex & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For:**

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients. 2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.


SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report









FH.12091159 PATIENT ID:

0022VJ006201 ACCESSION NO: DRAWN: 31/10/2022 09:47:00

AGE: 28 Years SFX: Male

RECEIVED: 31/10/2022 09:47:33

ABHA NO:

REPORTED:

31/10/2022 13:15:26

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLIENT PATIENT ID: UID:12091159

CLINICAL INFORMATION:

Test Report Status

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Results

Biological Reference Interval

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opi addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

recommended for detecting a hemoglobinopathy

CLINICAL PATH

URINALYSIS

PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD: PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL

SPECIFIC GRAVITY

>=1.030

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

CHEMICAL EXAMINATION, URINE

55

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

PROTEIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

NOT DETECTED

NOT DETECTED **GLUCOSE** METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

NOT DETECTED

NOT DETECTED BLOOD

BII IRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NITRITE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report









FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO: 0022VJ006201

AGE: 28 Years

SEX: Male

ABHA NO:

31/10/2022 13:15:26

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status <u>Final</u>	Results	Biological Reference	Biological Reference Interval		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED			
METHOD: REFLECTANCE SPECTROPHOTOMETRY, EST	ERASE HYDROLYSIS ACTIVITY				
MICROSCOPIC EXAMINATION, URINE					
PUS CELL (WBC'S)	0-1	0-5	/HPF		
METHOD: MICROSCOPIC EXAMINATION					
EPITHELIAL CELLS	1-2	0-5	/HPF		
METHOD: MICROSCOPIC EXAMINATION			2017202		
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF		
METHOD: MICROSCOPIC EXAMINATION	2				
CASTS	NOT DETECTED				
METHOD: MICROSCOPIC EXAMINATION					
CRYSTALS	NOT DETECTED				
METHOD: MICROSCOPIC EXAMINATION					
BACTERIA	NOT DETECTED	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION		NOT DETECTED			
YEAST	NOT DETECTED	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION		DIG EVANINATION DONE ON L	IDTNADV		
REMARKS		URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.			

Interpretation(s)
MICROSCOPIC EXAMINATION, URINE-

MICKOSCOPIC EXAMINATION, UKINERoutine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders
Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic protein dehydration, urinary tract infections and acute illness with fever
Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain

medications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous exercise. Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders.

Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retain.

bladder prior to collection.

pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type

can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus.

Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

End Of Report Please visit www.srlworld.com for related Test Information for this accession

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report









PATIENT NAME: MR. MR.ANIL REDDY DAMMA

FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

SEX: Male AGE: 28 Years

ABHA NO:

31/10/2022 13:15:26

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status Final Results


Biological Reference Interval

Dr.Akta Dubey **Counsultant Pathologist**

Dr. Rekha Nair, MD Microbiologist

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report









FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

AGE: 28 Years

SFX: Male

ABHA NO:

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

31/10/2022 15:12:40

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status

Final

Results

Biological Reference Interval

Unit

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

101.8

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

7.68

5.1 - 14.1

μg/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

4.440

High 0.270 - 4.200

µIU/mL

TSH 3RD GENERATION METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

Comments

NOTE: PLEASE CORRELATE VALUES OF THYROID FUNCTION TEST WITH THE

CLINICAL & TREATMENT HISTORY OF THE PATIENT.

Interpretation(s)
THYROID PANEL, SERUM-Triiodothyronine T3 , is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabore body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (T5H), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of T5H.
Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, T5H levels are significantly elevated, while in secondary and tertiary hypothyroidism, T5H levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, T5H & Total T3

Levels in TOTAL T4 TSH3G TOTAL T3

TOTAL T3

TOTAL T4 (yII)/mL) (ng/dL)

(μIU/mL) 0.1 - 2.5 0.2 - 3.0 (µg/dL) (ng/dL) Pregnancy First Trimester 81 - 190 6.6 - 12.4 6.6 - 15.5 100 - 260 100 - 260 2nd Trimester 0.3 - 3.06.6 - 15.5 3rd Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3 (µg/dL) (ng/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9 New Born: 75 - 260

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This i documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.
 Gowenlock A.H. Varley'''s Practical Clinical Biochemistry, 6th Edition.
 Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition

SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956







Scan to View Report









FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006201

SEX: Male 28 Years AGE :

ABHA NO:

31/10/2022 15:12:40

DRAWN: 31/10/2022 09:47:00

RECEIVED: 31/10/2022 09:47:33

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Biological Reference Interval

Test Report Status

Final

Results

Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

0.825

< 1.4

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with pros - PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the

Figure 1 is not detected to detect to be used in conjunction with other diagnostic procedures.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in Serial PSA can help detecting recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated a specific up to 3 weeks.

Specimens for total PSA assay should be obtained before biopsy, prostate things of prostate massage, since manipulation of the prostate giant may lead to elevated (false positive) levels persisting up to 3 weeks.
 As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific references.

range can be used as a guide lines-

Age of male Reference range (ng/ml)

40-49 years 0-2.5 50-59 years 0-3.5

60-69 years 70-79 years 0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)

References- Teitz , textbook of clinical chemiistry, 4th edition) 2. Wallach's Interpretation of Diagnostic Tests

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam

Birmbaddam

Consultant Pathologist

Tel: 9111591115,

CIN - U74899PB1995PLC045956

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA

Scan to View Details



Scan to View Report









PATIENT NAME: MR. MR.ANIL REDDY DAMMA

FH.12091159 PATIENT ID:

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006234

Final

SEX: Male 28 Years AGE:

ABHA NO: REPORTED:

31/10/2022 13:10:27

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

RECEIVED: 31/10/2022 12:17:36

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:12091159 REQNO-1313831

DRAWN: 31/10/2022 12:17:00

CORP-OPD

BILLNO-1501220PCR054258 BILLNO-1501220PCR054258

Test Report Status

Results

Biological Reference Interval

Unit

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

125

70 - 139

mg/dL

METHOD: HEXOKINASE

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insu GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and prandial glucose level may be seen due to effect of Oral Hypoglycaemics and

End Of Report Please visit www.srlworld.com for related Test Information for this accession


Dr.Akta Dubey

Counsultant Pathologist

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956 Email: -







Scan to View Report









PATIENT NAME: MR. MR.ANIL REDDY DAMMA

PATIENT ID:

FH.12091159

CLIENT PATIENT ID: UID:12091159

ACCESSION NO:

0022VJ006292

AGE: 28 Years

SEX: Male

ABHA NO:

31/10/2022 16:50:32

DRAWN: 31/10/2022 15:49:00

RECEIVED: 31/10/2022 16:05:29

REPORTED:

CLIENT NAME : HIRANANDANI HOSPITAL - VASHI -

REFERRING DOCTOR: DR. Prashant Dilip Pawar

CLINICAL INFORMATION:

UID:12091159 REQNO-11327751

IPD-TRIAGE

IPID-53923/22/1501 IPID-53923/22/1501

Results

Units

Test Report Status

Final

Biological Reference Interval

SEROLOGY

HEPATITIS B SURFACE ANTIGEN, SERUM

HEPATITIS B SURFACE ANTIGEN

NON REACTIVE

NON REACTIVE

METHOD: IMMUNOCHROMATOGRAPHY

HCV ABS, SERUM

HEPATITIS CABS

NON REACTIVE

NON REACTIVE

METHOD: IMMUNOCHROMATOGRAPHY

Interpretation(s)

HERALLIS B SUKFACE ANTIGEN, SEKUMHepatitis B is caused by infection with HBV, a enveloped DNA agent that is classified as hepadnavirus. This test detects the presence of viral surface antigen (HbsAg) in serum sample and is indicative of an active HBV infection, either acute or chronic.

Test Utility:

HbsAg is the first serologic marker appearing in the serum 6-16 weeks following hepatitis B viral infection. In typical HBV infection, HBsAg will be detected 2-4 weeks the liver enzyme levels (ALT) become abnormal and 3-5 weeks before patient develops jaundice. In acute cases HbsAg usually disappears 1-2 months after the onset the liver enzyme levels (ALT) become abnormal and 3-5 weeks before patient develops jaundice. In acute cases HbsAg usually disappears 1-2 months after the onset symptoms. Persistence of HbsAg for more than 6 months indicates development of either a chronic carrier state or chronic liver disease. The presence of HbsAg is frequently associated with infectivity. HbsAg when accompanied by Hepatitis Be antigen and/or hepatitis B viral DNA almost always indicates infectivity.

Limitations:
- For diagnostic purposes, results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute or chronic infection. If the antiresults are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
- HBsAg detection will only indicate the presence of surface antigens in the serum and should not be used as the sole criteria for diagnosis, staging or monitoring of hinfection This test may be negative during ""window period"" i.e. after disappearance of anti-HBs.
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed wit
- The current assay being a highly sensitive test, may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed with the majority of infected individuals may be asymptomatic, HCV infection may develop into chronic hepatitis, cirrhot and the majority of infected individuals may and/or increased risk of hepatocellular carcinoma.

Notes & Limitations:

- HCV antibody is typically not detected until approximately 14 weeks after infection (or 5 weeks after appearance of the first biochemical marker of illness) and is al always detectable by the late convalescent stage of infection.

- A negative result may also be observed due to loss of HCV antigen, years following resolution of always detectable by the late convalescent stage of infection.

- A negative result may also be observed due to loss of HCV antigen, years following resolution of infection. Infants born to hepatitis C infected mothers may have delayed seroconversion to anti-HCV. Hence a negative result should be evaluated cautiously with reciping infection. Infants born to hepatitis C infected mothers may have delayed seroconversion to anti-HCV infection. It is not be noted that absence of HCV antibodies does not imply an active Hepatitis C infection but is indicative of both past and/or recent infection. It has been reported that as many a representable of individuals receiving intravenous commercial immunoglobulin test falsely positive for HCV antibody. Also, patients with autoimmune liver disease may show a false HCV antibody result. Hence it is advisable to confirm a positive antibody result with a supplemental test. A positive result when followed by a positive supplemental HCV-RNA-PCR) suggests active hepatitis C infection.

End Of Report Please visit www.srlworld.com for related Test Information for this accession

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







Scan to View Report









PATIENT NAME: MR. MR.ANIL REDDY DAMMA

PATIENT ID: FH.12091159 CLIENT PATIENT ID: UID:12091159

ACCESSION NO: 0022VJ006292

AGE: 28 Years

SEX: Male

ABHA NO:

DRAWN: 31/10/2022 15:49:00 CLIENT NAME : HIRANANDANI HOSPITAL - VASHI -

<u>Final</u>

RECEIVED: 31/10/2022 16:05:29

REPORTED:

31/10/2022 16:50:32

REFERRING DOCTOR: DR. Prashant Dilip Pawar

CLINICAL INFORMATION:

UID:12091159 REQNO-11327751

IPD-TRIAGE

IPID-53923/22/1501 IPID-53923/22/1501

Test Report Status


Results

Biological Reference Interval

Units

Dr. Rekha Nair, MD Microbiologist







Scan to View Report



Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG

(For Billing/Reports & Discharge Summary only) PAN NO: AABCH5894D





DEPARTMENT OF NIC

Date: 09/Nov/2022

Name: Mr. Anil Reddy Damma

Age | Sex: 28 YEAR(S) | Male Order Station: FO-OPD

Bed Name:

UHID | Episode No : 12091159 | 53778/22/1501 Order No | Order Date: 1501/PN/OP/2210/114135 | 31-Oct-2022 Admitted On | Reporting Date : 31-Oct-2022 14:35:11

Order Doctor Name: Dr.SELF.

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- A tiny , homogenous , mass measuring about 10 x 7 mm at LV apex (? clot) .
- All apical segments of Left ventricle are severely hypokinetic. Rest of the left ventricle wall shows normal contractility.
- Mildly depressed left ventricle systolic function. LVEF approximately: 45%.
- No e/o left ventricle diastolic dysfunction. No e/o raised LVEDP.
- No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- No tricuspid regurgitation. No pulmonary hypertension.
- · IAS and IVS are intact.
- Normal right atrium and right ventricle dimension.
- Normal right ventricle systolic function. No hepatic congestion.
- IVC measures 15 mm with normal inspiratory collapse

M-MODE MEASUREMENTS:

	35	mm			
LA	29	mm			
AO Root	16	mm			
AO CUSP SEP	31	mm			
LVID (s)	43	mm			
LVID (d)	10	mm			
IVS (d)	the season of th	mm			
LVPW (d)	09	mm			
RVID (d)	29	mm			
RA	31	%			
LVEF	.45	70			

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG

PAN NO: AABCH5894D





(For Billing/Reports & Discharge Summary only)

DEPARTMENT OF NIC

Date: 09/Nov/2022

Name: Mr. Anil Reddy Damma

Age | Sex: 28 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No: 12091159 | 53778/22/1501

Order No | Order Date: 1501/PN/OP/2210/114135 | 31-Oct-2022

Admitted On | Reporting Date: 31-Oct-2022 14:35:11

Order Doctor Name : Dr.SELF.

DOPPLER STUDY:

E WAVE VELOCITY: 0.9 m/sec. A WAVE VELOCITY: 0.8 m/sec

E/A RATIO: 1.1

ii	PEAK	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
	N			Nil
MITRAL VALVE	05			Nil
AORTIC VALVE	03			Nil
TRICUSPID VALVE	N	-		Nil
PULMONARY VALVE	2.0			

Final Impression:

- IHD with mild LV systolic dysfunction.
- RWMA as above.
- · A tiny, homogenous, mass at LV apex (? clot).

• No e/19 LV diastolic dysfunction.

DR. PRASHANT PAWAR DNB (MED), DNB (CARDIOLOGY) Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 31/Oct/2022

Name: Mr. Anil Reddy Damma Age | Sex: 28 YEAR(S) | Male

Order Station : FO-OPD

Bed Name:

UHID | Episode No : 12091159 | 53778/22/1501

Order No | Order Date: 1501/PN/OP/2210/114135 | 31-Oct-2022 Admitted On | Reporting Date : 31-Oct-2022 10:36:48

Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGINI SHAH

Thelah

DMRD., DNB. (Radiologist)